Although polyethylene glycol (PEG) extends the therapeutic availability time of aptamers, it does not improve binding efficacy and worse, it induces an immune response. 

Helixomer's RNA Origami (RNAO) platform technology enhances aptamer performance by structurally optimizing their arrangement and placing multiple aptamers on each molecule, significantly boosting efficacy while maintaining non-immunogenic properties. This platform also supports modular drug design, utilizing established mRNA production facilities for scalable synthesis, which allows for rapid adaptation of aptamers to various therapeutic needs.